Global Subcutaneous Injection Immunoglobulin Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Subcutaneous Injection Immunoglobulin Market Research Report 2024
Subcutaneous Immunoglobulin (SCIg) infusions are administered by slowly injecting purified immunoglobulin into fatty tissue underneath the skin. SCIg can be administered at home by patients or carers, using an infusion pump (spring loaded or battery powered) or by rapid push (a manual method that does not require a pump).
According to Mr Accuracy reports new survey, global Subcutaneous Injection Immunoglobulin market is projected to reach US$ 2786.8 million in 2029, increasing from US$ 1864 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Subcutaneous Injection Immunoglobulin market research.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Subcutaneous Injection Immunoglobulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Takeda
Grifols
CSL
Segment by Type
10% Purity
20% Purity
Primary Immunodeficiency
Secondary Immunodeficiency
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Subcutaneous Injection Immunoglobulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Subcutaneous Injection Immunoglobulin market is projected to reach US$ 2786.8 million in 2029, increasing from US$ 1864 million in 2022, with the CAGR of 5.8% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Subcutaneous Injection Immunoglobulin market research.
The market growth can be attributed to several factors. Firstly, the increasing prevalence of bleeding disorders, driven by factors such as genetic predisposition, aging population, and improved diagnostic capabilities, has fueled the demand for coagulation factor products. Additionally, advancements in recombinant DNA technology and biotechnology have enabled the development of highly purified and more effective coagulation factor concentrates, offering improved treatment options for patients.Furthermore, the rising awareness about bleeding disorders and the availability of comprehensive treatment programs have contributed to increased diagnosis rates and access to coagulation factor therapies. Improved reimbursement policies and healthcare infrastructure have also played a role in expanding market reach.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Subcutaneous Injection Immunoglobulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Takeda
Grifols
CSL
Segment by Type
10% Purity
20% Purity
Segment by Application
Primary Immunodeficiency
Secondary Immunodeficiency
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Subcutaneous Injection Immunoglobulin report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices